Trials / Completed
CompletedNCT00040313
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial, in Parallel Groups, to Establish the Safety and Preliminary Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks for 12 to 30 Weeks to Patients With Clinically Significant Diabetic Macular Edema (CSME) Involving the Center of the Macula
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (planned)
- Sponsor
- Eyetech Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium (Macugen) |
Timeline
- Start date
- 2002-10-01
- Completion
- 2005-02-01
- First posted
- 2002-06-25
- Last updated
- 2006-05-03
Source: ClinicalTrials.gov record NCT00040313. Inclusion in this directory is not an endorsement.